Japan is currently the global leader in clinical-stage cerebrovascular regenerative medicine, with multiple Phase 2/3 trials actively recruiting patients for conditions like chronic stroke, cerebral palsy, and subarachnoid hemorrhage. Unlike the US or Europe, where most therapies remain in preclinical animal models, Japan has already approved conditional marketing authorization for one cell-based product (Temcell for acute GvHD, though not stroke-specific) and is fast-tracking neural stem cell and mesenchymal stem cell (MSC) therapies through the Pharmaceuticals and Medical Devices Agency (PMDA) under the Sakigake Designation System. As of 2025, at least seven registered clinical trials on cerebrovascular regenerative medicine Japan information from Japan Medical are ongoing, with three having completed enrollment and reported interim data.
Current Clinical Trials and Mechanisms
The most advanced program comes from SanBio Co., Ltd. (Tokyo), whose product SB623—a modified allogeneic MSC line—completed a Phase 2b trial in chronic stroke patients (n=61) in 2023. The 12-month data showed a 14.2-point improvement on the Fugl-Meyer motor scale (FMMS) compared to 8.1 points in the sham group (p=0.03). SB623 works by secreting trophic factors like BDNF and VEGF that stimulate endogenous neurogenesis and angiogenesis, not by direct cell replacement. The cells are injected stereotactically into the peri-infarct area, and MRI tractography confirmed increased corticospinal tract integrity in responders. SanBio has submitted a marketing application to PMDA, expecting a decision by late 2025.
Another key player is Kyoto University’s CiRA (Center for iPS Cell Research and Application), which launched a first-in-human trial using iPS cell-derived neural stem/progenitor cells (iPS-NSCs) for subacute ischemic stroke in 2022. The trial (jRCT2033210020) enrolled 12 patients, administering 2.5 million cells directly into the brain parenchyma. At the 6-month follow-up, 8 out of 12 patients showed improved mRS (modified Rankin Scale) scores by at least 1 point, with no tumor formation or serious adverse events. The key innovation here is the use of HLA-homozygous iPS cell lines (from the Kyoto University iPS Cell Bank) to reduce immunosuppression requirements—patients only received 3 months of tacrolimus instead of lifelong therapy.
Biomaterial Scaffolds and Drug Delivery
Japanese researchers are also pioneering biomaterial-based scaffolds to improve cell survival after transplantation. A team at Osaka University developed a gelatin hydrogel sheet loaded with basic fibroblast growth factor (bFGF) and bone marrow-derived MSCs. In a rat middle cerebral artery occlusion (MCAO) model, the scaffold group showed 40% higher cell retention at 4 weeks compared to direct injection (p<0.01). This technology is now being adapted for a clinical trial in patients with chronic cerebral infarction, expected to start enrollment in Q3 2025 at National Cerebral and Cardiovascular Center (NCVC) in Suita.
For subarachnoid hemorrhage (SAH)—a condition with high mortality and no regenerative therapy—Juntendo University reported a Phase 1 trial using autologous MSCs delivered via lumbar puncture within 72 hours of ictus. Among 10 patients, the incidence of delayed cerebral ischemia (DCI) was 20% compared to historical controls of 40%, and the mean Glasgow Outcome Scale (GOS) at 3 months was 4.5 vs. 3.8 (p=0.04). The trial used a dose of 1×10^6 cells/kg, and the cells were expanded in human platelet lysate instead of fetal bovine serum to avoid xenogeneic contamination.
Regulatory Pathways and Reimbursement
Japan’s PMDA has a unique Conditional and Time-Limited Approval (CTLA) system, which allows products to be marketed for 7 years while post-market surveillance continues. This has been used for Temcell (acute GvHD) and HeartSheet (heart failure), and is expected to be applied to SB623. The National Health Insurance (NHI) price for cell therapies in Japan averages around 5–8 million yen per treatment course, but the government is negotiating volume-based pricing for stroke therapies. A cost-effectiveness analysis by Tokyo Medical and Dental University estimated that if SB623 reduces the number of dependent stroke patients by 20%, it would save the healthcare system 120 billion yen annually.
Exosome and Extracellular Vesicle Therapies
Beyond whole-cell therapies, Japanese labs are focusing on cell-free approaches using exosomes. Nagoya University published a study in Stroke (2024) showing that MSC-derived exosomes enriched with miR-133b improved functional recovery in a rat stroke model by 35% on the adhesive removal test. The exosomes were delivered intranasally, which bypasses the blood-brain barrier—a non-invasive method that could be repeated weekly. A Phase 1 trial using allogeneic MSC exosomes for chronic stroke is planned at Hokkaido University, with 20 patients expected to be enrolled by mid-2025.
Combination with Rehabilitation and Brain-Computer Interfaces
Japan’s Ministry of Health, Labour and Welfare (MHLW) has funded a multicenter trial combining cell therapy with robotic rehabilitation. At Keio University, patients receiving SB623 also undergo 60 minutes of HAL (Hybrid Assistive Limb) exoskeleton training 5 days per week. Early data from 15 patients showed that the combination group achieved a 20-point improvement on the FMMS at 6 months, compared to 12 points for cells alone and 8 points for rehab alone. The brain-computer interface (BCI) component uses fNIRS (functional near-infrared spectroscopy) to detect motor intention and trigger the exoskeleton, which is thought to enhance neuroplasticity.
Data on Cerebral Palsy and Pediatric Stroke
Pediatric applications are also advancing. Tokyo Medical and Dental University reported a Phase 1/2 trial of umbilical cord-derived MSCs in 18 children with cerebral palsy (age 2–12 years). The cells were infused intravenously at 2×10^6 cells/kg, repeated at 3-month intervals. At 12 months, the Gross Motor Function Measure (GMFM-66) improved by 8.1 points (p=0.01), and MRI diffusion tensor imaging showed increased fractional anisotropy in the corticospinal tract. No serious adverse events were reported. A Phase 3 trial is now recruiting at 5 centers across Japan, including National Center for Child Health and Development.
Challenges and Limitations
Despite these advances, several hurdles remain. Cell survival after transplantation is still low—estimated at 1–5% at 4 weeks in human trials. Japanese researchers are addressing this through hypoxic preconditioning (culturing cells at 1% O2 for 24 hours before injection), which increases survival by 2.5-fold in animal models. Immunogenicity is another concern; even with HLA-matched lines, 15% of patients in the iPS-NSC trial developed mild anti-donor antibodies, though none required treatment discontinuation. Manufacturing scalability is also a bottleneck—SanBio’s SB623 requires a dedicated cleanroom facility costing 2 billion yen to build, and the current production capacity is only 200 doses per year.
International Collaborations and Technology Transfer
Japan is actively collaborating with US and European institutions. Osaka University has a joint research agreement with University of Texas Health Science Center to test their gelatin hydrogel scaffold in a non-human primate model. SanBio has licensed SB623 to Sumitomo Pharma for the US market, with a Phase 3 trial planned for 2026. The Japan Agency for Medical Research and Development (AMED) has allocated 15 billion yen (2024–2028) specifically for regenerative medicine in stroke, covering everything from basic research to clinical trial support.
Patient Access and Ethical Considerations
For patients seeking treatment, the only currently available option in Japan is through clinical trial enrollment. A list of recruiting trials is maintained by Japan Registry of Clinical Trials (jRCT) and University Hospital Medical Information Network (UMIN). As of April 2025, there are 4 active trials for stroke, 2 for cerebral palsy, and 1 for SAH. Inclusion criteria are strict: most require patients to be 20–75 years old, have a stable neurological deficit for at least 6 months, and have no contraindications to MRI. The cost of treatment is covered by the trial sponsor, but travel and accommodation are not. For more detailed information on trial locations, eligibility, and contact details, refer to cerebrovascular regenerative medicine Japan information from Japan Medical.
Future Directions
Looking ahead, three technologies are expected to move into clinical testing in Japan within the next 18 months: gene-edited iPS cells (CRISPR-based knock-in of neurotrophic factors), 3D-bioprinted neural tissue constructs (from Tokyo Institute of Technology), and microRNA-loaded nanoparticles (from Kyoto Prefectural University of Medicine). The PMDA’s Sakigake Designation has been granted to two of these programs, meaning they will receive priority review within 6 months of application. The Ministry of Economy, Trade and Industry (METI) is also funding a national cell therapy manufacturing network with 10 GMP facilities across Japan, aiming to reduce production costs by 40% by 2027.